Please provide your email address to receive an email when new articles are posted on . The device (TriGuard 3, Keystone Heart) showed potential to prevent larger ischemic brain lesions, Jeffrey W.

A US Food and Drug Administration (FDA) advisory panel struggled to muster support for marketing clearance of the TriGuard 3 (Keystone Heart) device for use during transcatheter aortic valve ...

The first day at the recently concluded Transcatheter Cardiovascular Therapies (TCT) meeting in Washington, D.C., was reportedly heavily focused on TAVR - transcatheter aortic valve replacement ...

CHICAGO -- Tweaks made to Medtronic's CoreValve transcatheter heart valve (THV) line in the last few years have tracked with some improved outcomes after transcatheter aortic valve replacement (TAVR), ...

A device designed to remove embolic material—fragments of tissue that can be released into the bloodstream during transcatheter aortic valve replacement (TAVR)—did not result in a reduction in the ...

This story was originally published on MedTech Dive. To receive daily news and insights, subscribe to our free daily MedTech Dive newsletter. Pi-Cardia received Food and Drug Administration clearance ...

The potential is high for TAVR adoption in emerging markets, according to Venkat Rajan, an analyst at Frost & Sullivan. “It is, however, coming in at a higher price point than traditional valves,” he ...

PHOENIX -- The newer generation Evolut transcatheter aortic valve replacement (TAVR) device improved on procedural and possibly safety characteristics, the TVT registry showed. The Evolut FX device ...

For a balloon-expandable transcatheter aortic valve replacement (TAVR or TAVI) platform, the much-litigated Myval performed well enough in the COMPARE-TAVI 1 randomized trial, but its rates of ...